CD274 and cancer: The past two decades have ushered in a new strategy, hailed as “immunotherapy”, involving reversal of a dampening effect that cancer cells unleash through cell-surface PD-L1 molecules, which bind to PD-1 molecules expressed by the T-cells to silence these adaptive immune cells [46].